Inventiva is a clinical stage biopharmaceutical company with an expertise in fibrosis, oncology and orphan diseases. It focuses on diseases with a high unmet medical need where either no treatments are available, such as NASH and Systemic Sclerosis, or the current standard of care leaves important manifestations of the diseases unaffected, as it is the case in many lysosomal storage diseases. Its lead product candidate is Lanifibranor that is Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. The Company also develops Odiparcil, which is Phase IIa clinical trial for the treatment of mucopolysaccharidosis I, II and VI diseases; YAP-TEAD that is in preclinical stage to treat malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment.
Market capitalization (12-May-2021)
Closing stock price (12-May-2021)
When was Inventiva founded?
Inventiva was founded in 2011.
Who are Inventiva key executives?
Inventiva's key executives are Frédéric Cren, Pierre Broqua and Michael Cooreman.
How many employees does Inventiva have?
Inventiva has 88 employees.
Who are Inventiva competitors?
Competitors of Inventiva include ImmVira, NOXXON Pharma and Plus Therapeutics.
Where is Inventiva headquarters?
Inventiva headquarters is located at 50 Rue de Dijon, Daix.
Where are Inventiva offices?
Inventiva has an office in Daix.
How many offices does Inventiva have?
Inventiva has 1 office.
Receive alerts for 300+ data fields across thousands of companies